Toxic epidermal necrosishttps://en.wikipedia.org/wiki/Toxic_epidermal_necrolysis
Ko te Toxic epidermal necrosis he momo tauhohenga kiri kino. Ko nga tohu tuatahi ko te kirika me nga tohu rewharewha. He torutoru nga ra i muri mai ka timata te kiri ki te opupu me te tihorenga ka puta he wahi kirikiri mamae. He mea nui kia uru mai nga kiriuhi mucous, penei i te waha. Ko nga raruraru ko te mate wai, te sepsis, te pneumonia, me te ngoikore o te okana maha.

Ko te tino take ko etahi rongoa penei i te lamotrigine, carbamazepine, allopurinol, sulfonamide antibiotic, me te nevirapine. Ko nga mea morearea ko te HIV me te systemic lupus erythematosus. I te nuinga o te wa ka mahia nga maimoatanga i te hohipera penei i te waahi wera, i te waahanga tiaki kaha ranei.

Maimoatanga
He mate kino tenei, na, ki te pangia to ngutu, waha ranei, ka pupuhi ranei to kiri, haere wawe ki to taakuta.
Me whakamutua nga rongoa whakapae. (hei tauira, nga patu paturopi, nga raau taero anti-inflammatory kore-steroidal)

☆ I te 2022 Stiftung Warentest hua mai i Tiamana, he iti noa iho te pai o nga kaihoko ki a ModelDerm i nga korero mo te waea rongoa utu.
  • Te mate kiri ahua o Toxic epidermal necrosis
  • TENS ― ra 10
  • Necrolysis epidermalis toxica
  • Ka tere haere te opupu o te atamira ka uru ki te tinana katoa i roto i nga ra torutoru.
References Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis: A Review of Diagnosis and Management 34577817 
NIH
Ko te Stevens-Johnson Syndrome (SJS) me te Toxic Epidermal Necrolysis (TEN) he onge nga ahuatanga ka pa te kiri ki te necrosis me te whakaheke. Mo te maimoatanga, he tino whai hua te cyclosporine mo te SJS, i te mea ko te huinga o te immunoglobulin (IVIg) me te corticosteroids he pai rawa atu mo nga keehi o te SJS me te TEN.
Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) are rare diseases that are characterized by widespread epidermal necrosis and sloughing of skin. Regarding treatment, cyclosporine is the most effective therapy for the treatment of SJS, and a combination of intravenous immunoglobulin (IVIg) and corticosteroids is most effective for SJS/TEN overlap and TEN.
 Toxic Epidermal Necrolysis: A Review of Past and Present Therapeutic Approaches 36469487
Ko te Toxic epidermal necrolysis (TEN) he tauhohenga kiri kino na etahi rongoa me nga mahi a te punaha aukati, ka puta te wehenga nui o te paparanga kiri o waho (epidermis) , ka pa atu i te 30% o te mata o te tinana. Neke atu i te 20% te nui o te mate mo te TEN, i te nuinga o nga wa na te mate me te uaua o te manawa. Ko te whakamutu i te rongoa ka puta te hohenga, te whakarato i te manaaki tautoko, me te whakamahi i etahi atu maimoatanga ka pai ake te putanga. Ko nga rangahau o tata nei i whakaatu ko nga raau taero penei i te cyclosporine, te aukati alpha necrosis factor, me te whakakotahitanga o te globulin aukati me te corticosteroids ka taea te awhina, i runga i nga whakamatautau me nga tātaritanga o nga rangahau maha.
Toxic epidermal necrolysis (TEN) is a serious skin reaction caused by certain medications and immune system activity, resulting in large-scale detachment of the outer skin layer (epidermis), affecting more than 30% of the body's surface. TEN has a mortality rate of over 20%, often due to infections and breathing difficulties. Stopping the medication causing the reaction, providing supportive care, and using additional treatments can improve the outcome. Recent studies have shown that drugs like cyclosporine, tumor necrosis factor alpha inhibitors, and a combination of intravenous immune globulin and corticosteroids can be helpful, based on randomized controlled trials and analyses of multiple studies.
 Toxic Epidermal Necrolysis and Steven–Johnson Syndrome: A Comprehensive Review 32520664 
NIH
Recent Advances: There is improved understanding of pain and morbidity with regard to the type and frequency of dressing changes. More modern dressings, such as nanocrystalline, are currently favored as they may be kept in situ for longer periods. The most recent evidence on systemic agents, such as corticosteroids and cyclosporine, and novel treatments, are also discussed.